As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible f...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!